Caplight Directory>Companies>RxAnte-preview>Rxante


RxAnte

RxAnte

Private
Portland, MaineN/Ahttps://www.rxante.com/

Last Round

Private Equity

Jan 12, 2026

Total Funding Raised

$19.5M

Company Overview

RxAnte is a healthcare technology systems company that provides predictive analytics and targeted clinical programs intended to improve medication prescribing and adherence.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RxAnte Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

RxAnte Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Private EquityJan 12, 2026
DebtDec 20, 2022
Growth EquityOct 5, 2016
Series ASep 1, 2012
View all Funding Rounds

Key People

Founding team and executive leadership

Josh Benner

Chief Executive Officer

Executive Team

RxAnte Investors

Notable investors and investment history

InvestorRounds
PNC Erieview CapitalPrivate Equity
Primus Capital PartnersPrivate Equity
Aberdare VenturesSeries A
Trinity CapitalDebt
Gary and Mary West Health Investment FundSeries A
UPMC EnterprisesPrivate Equity, Growth Equity
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    Primus Capital Partners led the round with UPMC Enterprises and PNC Erieview Capital also participating.

  • May 1, 2025

    Monthly visitors grew 166% MoM, reaching 33K.

View all signals

RxAnte Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RxAnte Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RxAnte's valuation, stock price, and market status.

Firmographic Details

HeadquartersPortland, Maine
Employee Range95
Year Founded2011
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.